↓ Skip to main content

Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses

Overview of attention for article published in BMC Medical Genomics, October 2011
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
35 Dimensions

Readers on

mendeley
63 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses
Published in
BMC Medical Genomics, October 2011
DOI 10.1186/1471-2350-12-131
Pubmed ID
Authors

Stella Trompet, Anton JM de Craen, Iris Postmus, Ian Ford, Naveed Sattar, Muriel Caslake, David J Stott, Brendan M Buckley, Frank Sacks, James J Devlin, P Eline Slagboom, Rudi GJ Westendorp, J Wouter Jukema, the PROSPER study group

Abstract

The PHArmacogenetic study of Statins in the Elderly at risk (PHASE) is a genome wide association study in the PROspective Study of Pravastatin in the Elderly at risk for vascular disease (PROSPER) that investigates the genetic variation responsible for the individual variation in drug response to pravastatin. Statins lower LDL-cholesterol in general by 30%, however not in all subjects. Moreover, clinical response is highly variable and adverse effects occur in a minority of patients. In this report we first describe the rationale of the PROSPER/PHASE project and second show that the PROSPER/PHASE study can be used to study pharmacogenetics in the elderly.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 63 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 2%
Unknown 62 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 12 19%
Researcher 10 16%
Student > Master 9 14%
Other 7 11%
Student > Bachelor 4 6%
Other 6 10%
Unknown 15 24%
Readers by discipline Count As %
Medicine and Dentistry 18 29%
Agricultural and Biological Sciences 12 19%
Biochemistry, Genetics and Molecular Biology 8 13%
Pharmacology, Toxicology and Pharmaceutical Science 3 5%
Nursing and Health Professions 2 3%
Other 3 5%
Unknown 17 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 October 2011.
All research outputs
#20,656,820
of 25,374,647 outputs
Outputs from BMC Medical Genomics
#1,682
of 2,444 outputs
Outputs of similar age
#122,102
of 145,922 outputs
Outputs of similar age from BMC Medical Genomics
#21
of 25 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,444 research outputs from this source. They receive a mean Attention Score of 4.4. This one is in the 17th percentile – i.e., 17% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 145,922 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one is in the 4th percentile – i.e., 4% of its contemporaries scored the same or lower than it.